BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 31781598)

  • 21. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.
    Turajlic S; Litchfield K; Xu H; Rosenthal R; McGranahan N; Reading JL; Wong YNS; Rowan A; Kanu N; Al Bakir M; Chambers T; Salgado R; Savas P; Loi S; Birkbak NJ; Sansregret L; Gore M; Larkin J; Quezada SA; Swanton C
    Lancet Oncol; 2017 Aug; 18(8):1009-1021. PubMed ID: 28694034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets.
    Zhou S; Liu S; Zhao L; Sun HX
    Front Oncol; 2022; 12():786438. PubMed ID: 35387130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer.
    Liang H; Xu Y; Chen M; Zhao J; Zhong W; Liu X; Gao X; Li S; Li J; Guo C; Jia H; Wang M
    Front Immunol; 2021; 12():749461. PubMed ID: 35356154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast Cancer Neoantigens Can Induce CD8
    Zhang X; Kim S; Hundal J; Herndon JM; Li S; Petti AA; Soysal SD; Li L; McLellan MD; Hoog J; Primeau T; Myers N; Vickery TL; Sturmoski M; Hagemann IS; Miller CA; Ellis MJ; Mardis ER; Hansen T; Fleming TP; Goedegebuure SP; Gillanders WE
    Cancer Immunol Res; 2017 Jul; 5(7):516-523. PubMed ID: 28619968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.
    Park H; Cho SY; Kim H; Na D; Han JY; Chae J; Park C; Park OK; Min S; Kang J; Choi B; Min J; Kwon JY; Suh YS; Kong SH; Lee HJ; Liu ET; Kim JI; Kim S; Yang HK; Lee C
    Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12492-7. PubMed ID: 26401016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer.
    Lo W; Parkhurst M; Robbins PF; Tran E; Lu YC; Jia L; Gartner JJ; Pasetto A; Deniger D; Malekzadeh P; Shelton TE; Prickett T; Ray S; Kivitz S; Paria BC; Kriley I; Schrump DS; Rosenberg SA
    Cancer Immunol Res; 2019 Apr; 7(4):534-543. PubMed ID: 30709841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies.
    Lo AA; Wallace A; Oreper D; Lounsbury N; Havnar C; Pechuan-Jorge X; Wu TD; Bourgon R; Jones R; Krogh K; Yang GY; Zill OA
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads.
    Lussier DM; Alspach E; Ward JP; Miceli AP; Runci D; White JM; Mpoy C; Arthur CD; Kohlmiller HN; Jacks T; Artyomov MN; Rogers BE; Schreiber RD
    Proc Natl Acad Sci U S A; 2021 Jun; 118(24):. PubMed ID: 34099555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer.
    Yin Q; Tang J; Zhu X
    Brief Funct Genomics; 2019 Mar; 18(2):119-128. PubMed ID: 29982317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting Neoantigens for Personalised Immunotherapy.
    Pritchard AL
    BioDrugs; 2018 Apr; 32(2):99-109. PubMed ID: 29516371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular classification reveals the diverse genetic and prognostic features of gastric cancer: A multi-omics consensus ensemble clustering.
    Hu X; Wang Z; Wang Q; Chen K; Han Q; Bai S; Du J; Chen W
    Biomed Pharmacother; 2021 Dec; 144():112222. PubMed ID: 34607103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. neoANT-HILL: an integrated tool for identification of potential neoantigens.
    Coelho ACMF; Fonseca AL; Martins DL; Lins PBR; da Cunha LM; de Souza SJ
    BMC Med Genomics; 2020 Feb; 13(1):30. PubMed ID: 32087727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer.
    Ren Y; Cherukuri Y; Wickland DP; Sarangi V; Tian S; Carter JM; Mansfield AS; Block MS; Sherman ME; Knutson KL; Lin Y; Asmann YW
    Oncoimmunology; 2020; 9(1):1744947. PubMed ID: 32523802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer immunotherapy targeting neoantigens.
    Lu YC; Robbins PF
    Semin Immunol; 2016 Feb; 28(1):22-7. PubMed ID: 26653770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites.
    Lim B; Kim C; Kim JH; Kwon WS; Lee WS; Kim JM; Park JY; Kim HS; Park KH; Kim TS; Park JL; Chung HC; Rha SY; Kim SY
    Oncotarget; 2016 Feb; 7(7):8055-66. PubMed ID: 26811494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Associations of
    Shen X; Zhao Y; Chen X; Sun H; Liu M; Zhang W; Jiang F; Li P
    Future Oncol; 2019 Jun; 15(16):1873-1894. PubMed ID: 30920860
    [No Abstract]   [Full Text] [Related]  

  • 39. Initial and crucial genetic events in intestinal-type gastric intramucosal neoplasia.
    Rokutan H; Abe H; Nakamura H; Ushiku T; Arakawa E; Hosoda F; Yachida S; Tsuji Y; Fujishiro M; Koike K; Totoki Y; Fukayama M; Shibata T
    J Pathol; 2019 Apr; 247(4):494-504. PubMed ID: 30474112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
    Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
    J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.